deltatrials
Completed PHASE1 INTERVENTIONAL 6-arm NCT02622074

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)

A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)

Sponsor: Merck Sharp & Dohme LLC

Conditions Triple Negative Breast Neoplasms
Interventions Anthracycline (doxorubicin) Carboplatin Cyclophosphamide Nab-paclitaxel Paclitaxel Pembrolizumab
Updated 17 times since 2017 Last updated: Aug 21, 2020 Started: Jan 27, 2016 Primary completion: May 31, 2018 Completion: Nov 18, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02622074, this PHASE1 trial focuses on Triple Negative Breast Neoplasms and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 17 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2019 · 15 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 20 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE1

  5. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 12 earlier versions

  1. Sep 2020 — Oct 2020 [monthly]

    Completed PHASE1

  2. Jul 2020 — Sep 2020 [monthly]

    Completed PHASE1

  3. Apr 2020 — Jul 2020 [monthly]

    Completed PHASE1

  4. Jan 2020 — Apr 2020 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Nov 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

  6. Aug 2018 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1

  8. Nov 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  9. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE1

  10. Jun 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  11. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.